In the competitive field of Nervous System Drugs, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Nervous System Drugs technology and learn how to protect your intellectual property.

Patent challenges are becoming increasingly common in the Nervous System Drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Nervous System Drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Nervous System Drugs industry

EP3340971Methods Of Treating Lennox-Gastaut Syndrome Using FenfluramineZOGENIX INTERNATIONAL LIMITEDNov 19, 2024KRAUS & LEDERER PARTGMBB
EP3454673Whey Preparation For Improving Brain DevelopmentARLA FOODS AMBANov 6, 2024N.V. NUTRICIA
EP3866765Injectable Long-Acting Naltrexone Microparticle CompositionsPURDUE RESEARCH FOUNDATIONNov 6, 2024ALKERMES PHARMA IRELAND LIMITED
EP3977993Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole For Use As A MedicamentPFIZER INC.Oct 31, 2024KELTIE LLP
EP3977993Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole For Use As A MedicamentPFIZER INC.Oct 29, 2024QUIMICA SINTETICA, S.A.
EP4025188Dosing Regimens Associated With Extended Release Paliperidone Injectable FormulationsJANSSEN PHARMACEUTICA NVOct 10, 2024GENERICS [UK] LIMITED
EP4025188Dosing Regimens Associated With Extended Release Paliperidone Injectable FormulationsJANSSEN PHARMACEUTICA NVOct 9, 2024HAMM&WITTKOPP PATENTANWALTE PARTMBB
EP4025187Dosing Regimens Associated With Extended Release Paliperidone Injectable FormulationsJANSSEN PHARMACEUTICA NVOct 4, 2024HAMM&WITTKOPP PATENTANWALTE PARTMBB
EP4025187Dosing Regimens Associated With Extended Release Paliperidone Injectable FormulationsJANSSEN PHARMACEUTICA NVOct 3, 2024GENERICS [UK] LIMITED
EP3744326Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICALS, INC.Sep 6, 2024ADVANZ PHARMA SERVICES (UK) LTD.

To stay ahead in the competitive Nervous System Drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the Nervous System Drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Patent NumberGrant DateTitleApplicantTotal Oppositions
EP2234617Mar 31, 2021Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICA NV20
EP2949335Jan 4, 2017Low Frequency Glatiramer Acetate TherapyYEDA RESEARCH & DEVELOPMENT COMPANY, LTD.11
EP3744326Dec 6, 2023Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICALS, INC.9
EP3280416Apr 22, 2020Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICALS, INC.8
EP2350096Dec 11, 2019Methods Of Treating Hepatic EncephalopathySALIX PHARMACEUTICALS, LTD.8
EP2340828Jul 15, 2020Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep InhibitorNOVARTIS PHARMA GMBH8
EP2962686Apr 10, 2019Dosage Form Containing Oxycodone And NaloxoneEURO-CELTIQUE S.A.7
EP3103443Jun 30, 2021Method For Treating Primary InsomniaNEURIM PHARMACEUTICALS (1991) LIMITED6
EP1731152May 1, 2013Sustained Analgesia Achieved With Transdermal Delivery Of BuprenorphineMUNDIPHARMA PHARMACEUTICALS B.V.5
EP2630962Jun 27, 2018Low Frequency Glatiramer Acetate TherapyYEDA RESEARCH & DEVELOPMENT COMPANY, LTD.5